Ghrelin receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-14. Anything still debated is marked as such rather than presented as settled.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Contains two non-natural residues |
| Molecular formula | C38H49N9O5 | Free base form |
| Molecular weight | 711.85 g/mol | Calculated from formula |
| Primary target | GHS-R1a ghrelin receptor | Agonist activity |
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Quality control for research-grade ipamorelin is not governed by a single harmonized pharmacopeial monograph, so certificates of analysis vary between suppliers. Common tests include appearance, solubility, water content, peptide content by quantitative amino acid analysis, and residual counterion measurement. Independent verification by an outside laboratory is often used to confirm identity and purity claims. Salt form, counterion content, and residual solvent levels are frequently unspecified, which complicates direct comparison between lots and leaves reproducibility partly unresolved.
Identity and purity assessment of ipamorelin relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength where the peptide backbone absorbs. Mass confirmation is typically obtained by electrospray ionization mass spectrometry or by liquid chromatography coupled to mass spectrometry, comparing the observed mass with the calculated value. Amino acid analysis and peptide mapping after enzymatic digestion can confirm the sequence. Impurity profiles include deletion peptides, truncated fragments, and oxidation products, reported as relative area percentages.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
all the Francoist institutions without exception, so that the reform law actually liquidated what it was intended to reform. In addition, the new attitude of the government and especially that of its president changed the political climate, overcoming the tension that had been experienced during the government of Arias Navarro. On July 31, the government approved the amnesty, one of the main demands of the anti-Francoist opposition, although "blood crimes" were excluded, so that many "Basque prisoners", alleged members of ETA, remained in jail. This coupled with the fact that demonstrations in the Basque Country and Navarre were normally banned precisely because they included the request for amnesty for "Basque prisoners" and the claim for self-government which the authorities immediately linked to ETA activity ─ which continued with the attacks ─ would explain that there the climate of tension (and political radicalization) increased while in the rest of Spain it decreased. The obstacle that most worried the government to carry out the "political reform" was not what the democratic opposition could say, but rather the Army, that was considered the ultimate guarantor of "Franco's legacy". On September 8, Adolfo Suarez met with the military leadership to convince the high command of the need for reform.
=== Notable cases === 1994: Lucien Bouchard, future premier of Québec, Canada, who was infected while leader of the federal official opposition Bloc Québécois party, lost a leg to the illness. 1994: A cluster of cases occurred in Gloucestershire, in the west of England. Of five confirmed and one probable infection, two died. The cases were believed to be connected. The first two had acquired the Streptococcus pyogenes bacteria during surgery; the remaining four were community-acquired. The cases generated much newspaper coverage, with lurid headlines such as "Flesh Eating Bug Ate My Face". 1997: Jeff Moorad, former agent and partial owner of the San Diego Padres and Arizona Diamondbacks, contracted the disease. He had seven surgeries in a little more than a week and later fully recovered. 2004: Don Rickles, American stand-up comedian, actor, and author, known especially for his insult comedy, contracted the disease in his left leg. He had six operations and later recovered. The condition confined him in his later years to performing comedy from a chair. 2004: Eric Allin Cornell, winner of the 2001 Nobel Prize in Physics, lost his left arm and shoulder to the disease. 2005: Alexandru Marin, an experimental particle physicist, professor at MIT, Boston University, and Harvard University, and researcher at CERN and JINR, died from the disease. 2006: Alan Coren, British writer and satirist, announced in his Christmas column for The Times that his long absence as a columnist had been caused by his contracting the disease while on holiday in France. 2009: R. W.
== Work == The new São Paulo Institute was built in a section of the city named Butantan, at the time a far-away place, near the Pinheiros river, a swampy, sparsely inhabited area. Under Vital Brazil, it soon became an energetic and exemplary research center in vaccines and sera of all kinds, which were produced locally for the prophylaxis and treatment of tetanus, diphtheria, yellow fever, smallpox and several zoonoses (diseases transmitted to humans by animals), such as the dreaded hydrophobia. The Institute came to be well known by his original name, the Butantan Institute, and is still active today. Vital Brazil was convinced since his early work at Butantan that envenomations (poisoning by accidents with venomous animals, such as snakes, scorpions, spiders and batrachia, then the cause of thousands of deaths in Brazil) could be fought with antisera, i.e., antibodies specifically produced for venoms which were proteins or long-chain peptides. A French immunologist, Albert Calmette (1863–1933) had demonstrated this for the first time in 1892, by developing a monovalent serum to treat bites by the Indian cobra (Naja tripudians).
23 October A significant breakthrough in treating cervical cancer is reported by University College London, with participants in a Phase III trial seeing a 35% reduction in the risk of both mortality or the disease returning. The study used a combination of existing, cheap drugs ahead of usual radiotherapy treatment. The Royal Mint unveil a special Christmas 50 pence coin, celebrating the 1978 picture book The Snowman by Raymond Briggs. British-Israeli Yosef Guedalia is named as another victim killed by Hamas in the 7 October attack. Sunak tells parliament the UK has judged the al-Ahli Arab Hospital explosion, which occurred on 17 October, was likely caused by "a missile, or part of one" fired from "within Gaza". COVID-19 in the UK: Hospitals ask visitors to wear face-coverings amidst a rise in COVID-19 cases. 24 October Office for National Statistics data shows that UK unemployment remained at 4.2% in the three months up to August 2023. A BBC investigation finds that UK authorities failed to act on multiple official warnings about an online forum promoting suicide connected to at least 50 UK deaths. Immigration Minister Robert Jenrick confirms that the UK government will stop using 50 hotels to accommodate asylum seekers by January 2024. Local officials subsequently warn that local authorities may be forced to pay for use of the hotels instead. The Financial Conduct Authority confirms that the cap on bankers' bonuses, introduced in 2014, will be lifted from 31 October as part of post-Brexit financial reforms.
Sources: en.wikipedia.org
== History == Phenylpiracetam was first described in the scientific literature by 1983. It was developed in 1983 as a medication for Soviet cosmonauts to treat the prolonged stresses of working in space. Phenylpiracetam was created at the Russian Academy of Sciences Institute of Biomedical Problems in an effort led by psychopharmacologist Valentina Ivanovna Akhapkina (Валентина Ивановна Ахапкина). Subsequently, it became available as a prescription drug in Russia. It was approved in 2003 for treatment of various conditions. Pilot-cosmonaut Aleksandr Serebrov described being issued and using phenylpiracetam, as well as it being included in the Soyuz spacecraft's standard emergency medical kit, during his 197-days working in space aboard the Mir space station. He reported "the drug acts as the equalizer of the whole organism, "tidying it up", completely excluding impulsiveness and irritability inevitable in the stressful conditions of space flight."
Carrey's first stand-up comedy experience took place in 1977 at the age of 15 with his father trying to help him put together a stage act, driving him to downtown Toronto to debut at the recently opened Yuk Yuk's comedy club operating one-night-a-week out of community center The 519's basement on Church Street. For the performance, Carrey had his attire—a polyester leisure suit—chosen by his mother who reasoned "that's how they dress on The Dean Martin Celebrity Roast". Pubescent Carrey's conventional impersonations bombed, proving ill-suited for a club with a raunchy comedic sensibility and giving him doubts about his potential as a professional entertainer. Decades later, recalling Carrey's stand-up debut, Yuk Yuk's owner Mark Breslin described it as "bad Rich Little". His family's financial struggles made it difficult for them to support Carrey's show business ambitions. Eventually, the family's financial situation improved and they moved into a new home in Jackson's Point. With more domestic stability, Carrey returned to the stage in 1979 with a more polished act that led to his first paid gig: a 20-minute spot at the Hay Loft club on Highway 48 in Scarborough for a reported $20 compensation on a bill with the Mother of Pearl performer from The Pig and Whistle. He soon faced his fears and went back downtown to the site of his debacle from two years earlier—Yuk Yuk's that had in the meantime moved into a permanent location on Bay Street in the fashionable Yorkville district.
The FDA trade union which represents senior civil servants launches its High Court case against the UK government over the Rwanda asylum plan, arguing that they could be asked to break the law by ministers if they were asked to ignore a ruling from the European Court of Human Rights to halt a flight to Rwanda. Labour abandons legal action against five Corbyn-era employees who were accused of "conspiring" against Keir Starmer's leadership. It is revealed that the Conservatives accepted a further donation from Frank Hester after he was accused of making racist comments about Diane Abbott. 7 June – The legal deadline for candidates in the general election passes. Rishi Sunak apologises for leaving the D-day memorial early to return to the UK to give an ITV interview about the election. He says: "On reflection, it was a mistake not to stay in France longer – and I apologise." Keith Vaz, who stood down from Parliament after he was found to have "expressed willingness" to buy cocaine for male prostitutes, will stand in his old Leicester East constituency for the One Leicester Party. Mishal Husain moderates the first of the BBC's election debates featuring representatives from seven of the UK's political parties. Appearing on the programme are Penny Mordaunt (Conservative), Angela Rayner (Labour), Daisy Cooper (Liberal Democrats), Stephen Flynn (SNP), Rhun ap Iorwerth (Plaid Cymru), Carla Denyer (Green) and Nigel Farage (Reform UK). The Unite trade union says it will not endorse Labour's election manifesto because it does not go far enough on protecting the rights of workers.
Jet injector A device that uses high pressure to propel insulin through the skin and into the body. Juvenile onset diabetes Former term for insulin-dependent or type I diabetes. See: Insulin-dependent diabetes mellitus.
The Aviation Safety Reporting System (ASRS) collects voluntarily submitted aviation safety incident/situation reports from pilots, controllers and others. The ASRS uses reports to identify system deficiencies, issue alert messages, and produce two publications, CALLBACK, and ASRS Directline. The collected information is made available to the public, and is used by the FAA, NASA and other organizations working in research and flight safety.
Sources: en.wikipedia.org
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.
It acts as an agonist at the growth hormone secretagogue receptor, also known as the ghrelin receptor. Binding at pituitary somatotroph cells promotes growth hormone release.
Early studies report weaker effects on cortisol, prolactin, and appetite than compounds such as GHRP-6. The size of that difference in humans is not firmly established.
Dry powder is held at minus twenty degrees Celsius or colder, away from light and moisture. Sealed vials under inert gas limit degradation during storage.